• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

Despite a $45 million net worth, Big Bang Theory star Kunal Nayyar still works tough, 16-hour days—he repeats this mantra when he's overwhelmed

2

A $1,000 loan kept MacKenzie Scott in college—now the billionaire philanthropist is giving away her $37 billion fortune to pay it forward

3

Mark Cuban wants to solve wealth inequality by making employers choose between paying higher taxes or giving every member of staff company stock

1

Despite a $45 million net worth, Big Bang Theory star Kunal Nayyar still works tough, 16-hour days—he repeats this mantra when he's overwhelmed

2

A $1,000 loan kept MacKenzie Scott in college—now the billionaire philanthropist is giving away her $37 billion fortune to pay it forward

3

Mark Cuban wants to solve wealth inequality by making employers choose between paying higher taxes or giving every member of staff company stock
HealthChemical industry

DuPont Will Pay $5.1 Million for Causing Teflon-Related Cancer

By
Reuters
Reuters
and
Audrey Shi
Audrey Shi
Down Arrow Button Icon
By
Reuters
Reuters
and
Audrey Shi
Audrey Shi
Down Arrow Button Icon
July 7, 2016, 12:47 PM ET
Photo by Bloomberg via Getty Images
Add Fortune on Google for similar content.

A U.S. jury on Wednesday ordered DuPont (DD) to pay $5.1 million to a man who said he developed testicular cancer from exposure to a toxic chemical used to make Teflon at one of its plants, according to a DuPont spokesman.

It is the second time jurors in Ohio federal court have found against DuPont, which is facing more than 3,400 lawsuits from residents who say they contracted one of six diseases linked to perfluorooctanoic acid, known as PFOA or C-8, which is used to make products such as Teflon non-stick cookware.

Following a five-week trial, jurors deliberated for less than a day before finding DuPont was negligent and awarding $5.1 million in compensatory damages to David Freeman, an Ohio resident who said he developed testicular cancer from his exposure to C-8 in drinking water.

The jury also decided that DuPont had acted with actual malice, a finding that exposes the company to punitive damages, the amount of which will be determined at a proceeding starting Thursday.

A DuPont spokesman declined to comment. While DuPont is the named defendant, a recent spin-off of its performance chemicals segment, Chemours, will cover its liability.

A spokeswoman for Chemours, Cynthia Salitsky, said the verdict will be appealed. To the extent DuPont claims indemnification for the verdict, “Chemours retains its defenses to such claims,” she said in a statement.

Lawyers for Freeman did not immediately return a request for comment. The trial was a so-called bellwether, the verdict of which is intended to help the companies and plaintiffs value remaining cases alleging similar facts.

The first trial over C-8 exposure resulted in a $1.6 million verdict and no punitive damages last year.

 

Chemours shares closed down 22.5% at $5.93 in heavy volume. DuPont shares ended down 1.8% at $61.85 per share.

About the Authors
By Reuters
See full bioRight Arrow Button Icon
By Audrey Shi
See full bioRight Arrow Button Icon
Add Fortune on Google for similar content.

Latest in Health


Most Popular

Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    Latest in Health


    Most Popular

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.